Aduro Biotech (Aduro Biotech) Other Stockholders Equity : $-0.00 Mil (As of Jun. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Aduro Biotech Other Stockholders Equity?

Aduro Biotech's Other Stockholders Equity for the quarter that ended in Jun. 2020 was $-0.00 Mil.

Aduro Biotech's quarterly Other Stockholders Equity declined from Dec. 2019 ($-0.00 Mil) to Mar. 2020 ($-0.00 Mil) and declined from Mar. 2020 ($-0.00 Mil) to Jun. 2020 ($-0.00 Mil).

Aduro Biotech's annual Other Stockholders Equity declined from Dec. 2017 ($0.00 Mil) to Dec. 2018 ($-0.00 Mil) and declined from Dec. 2018 ($-0.00 Mil) to Dec. 2019 ($-0.00 Mil).

Aduro Biotech Other Stockholders Equity Historical Data

The historical data trend for Aduro Biotech's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aduro Biotech Other Stockholders Equity Chart

Aduro Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Other Stockholders Equity

Get a 7-Day Free Trial

Aduro Biotech Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Other Stockholders Equity	Get a 7-Day Free Trial															-	-	-	-	-

Aduro Biotech Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Aduro Biotech Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Aduro Biotech's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Aduro Biotech (Aduro Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aduro Biotech Inc (NAS:ADRO) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

740 Heinz Avenue, Berkeley, CA, USA, 94710

Website

https://www.aduro.com

Aduro Biotech Inc is a immunotherapy company focused on the discovery, development and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. Its primary technologies related are to the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand. The STING pathway activator technology is designed to activate the intracellular STING receptor. The APRIL is a soluble factor that binds to BCMA and TACI receptors thereby inducing signaling, and is implicated in IgA nephropathy.

Executives

Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
William Mariner Greenman	director	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Ross Haghighat	director	C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Dolca Thomas	director	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Tom Frohlich	officer: Chief Business Officer	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Eric Dobmeier	director, officer: President, CEO	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Davis Jerel	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I Parallel, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Vii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Andrew James King	officer: Head of Renal Discovery	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Alan Glicklich	officer: Chief Medical Officer	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Celeste Ferber	officer: SVP, GC and Secretary	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Blaine Templeman	officer: Chief Legal Officer	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710